Nurix Therapeutics

$28.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.28 (+4.73%) Today
$0.00 (0.00%) As of 6:00 PM EDT after-hours

Why Robinhood?

You can buy or sell NRIX and other stocks, options, and ETFs commission-free!

About NRIX

Nurix Therapeutics, Inc. Common stock, also called Nurix Therapeutics, is a biopharmaceutical company. Read More It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA. The listed name for NRIX is Nurix Therapeutics, Inc. Common stock.

Employees
93
Headquarters
San Francisco, California
Founded
2009
Market Cap
1.10B
Price-Earnings Ratio
Dividend Yield
Average Volume
69.78K
High Today
$28.80
Low Today
$26.48
Open Price
$27.29
Volume
61.87K
52 Week High
$37.46
52 Week Low
$15.21

Collections

NRIX Earnings

-$0.59
-$0.53
-$0.47
-$0.41
Q3 2020
Estimated
-$0.41 per share
Actual
-$0.59 per share

You May Also Like